Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase II study evaluating the safety
and efficacy of Atezolizumab when combined with immunogenic chemotherapy in subjects with
metastatic triple-negative breast cancer. Atezolizumab, pegylated liposomal doxorubicin and
cyclophosphamide are the Investigational Medicinal Products (IMPs).
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Helse Stavanger HF Hoffmann-La Roche Karolinska Institutet NanoString Technologies, Inc. Norwegian Cancer Society Rigshospitalet, Denmark St. Olavs Hospital Technical University of Denmark University Hospital of North Norway Vejle Hospital